• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Pfizer, already flush with cash, will reap $16B from selling shares in GSK consumer health...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 01, 2022 at 10:12: AM
via By combining its consumer health business with GSK's in 2019, Pfizer made clear its plan to focus on innovative medicines and vaccines. Now, in exiting the consumer market, the New York pharma is collecting a huge cash windfall.

article source
 

<



Similar threads

cafead
As Pfizer&#039;s booster AdComm nears, FDA staffers say COVID vaccines are already working...
Replies
0
Views
133
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer eyes $26B in COVID-19 vaccine sales for the year, with $3.5B already in the bag
Replies
0
Views
170
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote